Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ALZA’s BIO-ELECTRO UNIT TO MANAGE MEDTRONIC ELECTROTRANSPORT

Executive Summary

ALZA's BIO-ELECTRO UNIT TO MANAGE MEDTRONIC ELECTROTRANSPORT business unit under a "collaborative arrangement" between Alza, its Bio-Electro spinoff and Medtronic. Alza formed Bio-Electro in 1988 as an independent vehicle for the development of drug delivery systems based on Alza technology in bioerodible polymers and electrotransport drug delivery. Both Bio-Electro and Alza are located in Palo Alto, California. Medtronic currently has 25 people working in the electrotransport area at its facility in Spring Lake Park, Minnesota. A spokesperson said that under the new arrangement, Bio-Electro will "give direction to and coordinate" those efforts. Bio-Electro also "has obtained a $17 mil. bank line of credit to fund the electrotransport activities with Medtronic," a Feb. 5 release notes. Medtronic has one electrotransport product on the market: a cystic fibrosis indicator for pediatric use. The battery powered device delivers a low level electrical current to the patient's arm, exciting the sweat glands. The clinician then removes the device and applies a patch, which analyzes the chemical content of the sweat and indicates the likelihood of CF via a color change. Medtronic will receive an upfront payment of $2.9 mil., warrants to acquire 500,000 shares of Alza Class A common stock at $50 per share, and royalties on future electrotransport product sales by Bio-Electro. "In addition to this collaboration, Bio-Electro Systems has obtained an option, exercisable through June 1992, to acquire Medtronic's electrotransport technologies and business unit," a Feb. 5 release states. Alza holds an option to acquire Bio-Electro which is good through January 1995; if both options are exercised, Alza would own the electrotransport business of both companies. Shifting responsibility for expansion of the firm's electrotransport business to Bio-Electro fits with Medtronic's strategy to focus primarily on the cardiovascular and neurological markets, the Medtronic spokesperson said. Electrotransport is a logical research area for Alza, which already has a number of non-oral drug delivery products on the market in the form of transdermal patches. Alza has no commercial products based on electrotransport technology. The firm currently is evaluating electrotransport for the delivery of proteins and peptides developed by the biotech industry which cannot be delivered orally because they are destroyed by the digestive system. A commercial product is three to five years away, a spokesperson estimated. Bio-Electro has its own executives and board, but no other employees; the actual R&D is carried out by Alza staff ("The Pink Sheet" Oct. 24, 1988, p. 9). Bio-Electro was spun-off from Alza in a $43 mil. stock-warrant deal in late 1988. The Bio-Electro execs will oversee the collaboration with Medtronic.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel